IL15 and Hyperglycemia: We found that anti-CD132 monoclonal antibody (anti-CD132), which blocks IL-15 signalling, not only prevented the onset, but also synergistically reversed hyperglycemia with anti-CD3 monoclonal antibody (anti-CD3) in cyclophosphamide-accelerated NOD mice, which significantly enhances the clinical value of this study.